Most Pharmacies Express Readiness To Administer COVID-19 Vaccines Once Available

Pharmacy Industry Signals Confidence

Results of a forthcoming APhA survey show more than one-third of pharmacies are fully prepared to administer the vaccines once they are available, with more still preparing.

Doctor, nurse, scientist hand in blue gloves holding flu, measles, coronavirus, covid-19 vaccine disease preparing for child, baby, adult, man and woman vaccination shot, medicine and drug concept.
Most pharmacies expressed readiness to administer coronavirus vaccines • Source: Shutterstock

The COVID-19 vaccines from Moderna, Inc. and Pfizer Inc./BioNTech SE are neck-and-neck in terms of efficacy data and timing, but a number of requirements for Pfizer/BioNTech’s vaccine, particularly ultra-cold storage, could give an edge to Moderna’s product. A forthcoming survey by a pharmacist professional group will show that more than half of retail pharmacies – a likely destination for a lot of people seeking to get vaccinated – are fully prepared to administer vaccines as soon as they are available or making final preparations to ready themselves. Another third will not be able to participate in the first wave of vaccinations, but will be prepared for future phases.

Moderna announced it had filed mRNA-1273 for emergency use authorization from the US Food and Drug Administration on 30 November....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By 

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By 

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By 

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By 

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.